IL6 and Burkitt lymphoma: BGB324 markedly reduced p-STAT3 activity in BL PDAC cells, switched BL tumors toward a more differentiated CLA-like phenotype, and reduced the expression of stromal IL-6, particularly when combined with gemcitabine.